Screener
Parabilis Medicines PBLS Q3 2026 earnings
Reported November 12, 2026 · Before market open
Revenue$2.1MBeat by $1.7M
EPS-$0.36In line
Revenue estimate$375.0K
EPS estimate-$0.36
“The updated results presented at ESMO further reinforce our confidence in the depth and consistency of desmoid tumor responses, alongside a favorable safety and tolerability profile. With our Phase 3 dosing, regimen and trial design aligned with the FDA, we are well positioned to initiate PEDESTAL in the first half of 2027, bringing us closer to delivering a potentially transformative treatment for patients with desmoid tumors.”
Next report
Feb 11, 2027 (in 3 months)Revenue estimate$1.1M
EPS estimate-$0.42
Financials
Q3 2026Valuation & ratios
Versus estimates
Revenue
Q3 2026$2.1MBeat by $1.7M
Q2 2026$100.0KMiss by $16.6MDiluted EPS
Q3 2026-$0.36In line
Q2 2026-$2.32Miss by $2.16FAQ
- When did Parabilis Medicines report Q3 2026 earnings?
- Parabilis Medicines (PBLS) reported Q3 2026 earnings on November 12, 2026 before market open.
- What were Parabilis Medicines's Q3 2026 revenue and EPS?
- Parabilis Medicines reported revenue of $2.1M and eps of $-0.36 for Q3 2026.
- Did Parabilis Medicines beat estimates in Q3 2026?
- Revenue beat the consensus estimate of $375.0K by $1.7M. EPS beat the consensus estimate of $-0.36 by $0.00.
- Where can I find Parabilis Medicines's Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-456892) and the 10-Q periodic report (0001193125-26-458388) directly on SEC EDGAR. The filing index links above go to sec.gov.
